Vice President, Oncology Asset Team

Job Description

The Vice President, Oncology Asset Team is responsible and accountable for the end-to-end lifecycle management for our company's late-stage multi-tumor assets. This includes the breadth/depth of development across different disease TA sections, timing of studies across Disease Therapeutic Areas (TA) and timing of launches. The Vice President (VP) will work collaboratively with Oncology VP TA heads directly as well as through the interaction of Asset Teams and Disease Specific Product Development Teams (PDT) to evaluate potential indications in specific disease areas.

This individual will ensure effective and seamless cross functional collaboration of the ADTs with the respective Early-Stage Development teams (EDT) and PDTs by establishing credibility, securing appropriate sponsorship, establishing clarity of roles & responsibilities, effective decision making, and driving a culture of mutual respect across ADT and EDT/PDT teams.

The TA teams will make recommendations to the ADT regarding potential studies and development strategies for specific disease(s). TAs and PDTs (Tumor Teams) will be responsible for the conduct of agreed-upon tumor-specific Umbrella, Phase 2 and Phase 3 studies.

ADTs will be responsible for conducting or working with Translational Medicine to conduct clinical pharmacology studies (e.g. food effect, DDI, TQT, etc), as well as basket studies of an asset across multiple tumors. The AT will be responsible and accountable for ensuring consistency of asset related issues across TAs.

ADTs will work collaboratively across our company to ensure cross functional needs are met including CMC, Medical, Commercial Planning, Launch Sequencing, Access and other lifecycle management activities including IBs, DSURs, and other asset specific activities.

Primary Responsibilities:

• Responsible for broad strategic oversight and life-cycle management of individual assets with multi-disease area potential.

• Works with the TA heads to consider disease area prioritizations and how disease area priorities for an asset matrix with the individual asset prioritizations.

• Manages a group of Asset Team Leads who will develop individual molecule late-stage development plans; will work across TA areas to gain insights /expert advice regarding tumor specific development; will design and conduct basket studies for assets; will work with Early Oncology to advance biomarker strategies and ensures continuity of asset knowledge / strategies across PDTs.

• Empowers Asset Teams to develop Asset level strategy that can quickly respond to changing priorities and portfolio needs.

• Empowers Asset Teams that considers the full E2E development requirements and enables cross-Tumor Team execution and successful approval of the product.

• Ensures clinical programs and clinical studies are designed and monitored optimally. Ensures that clinical documents are of highest quality.

• Interfaces with functional leaders within Research & Development (e.g., Discovery, Translational Biomarkers, GCTO, BARDS, GRACS, TPharm), CORE, GHH, and Manufacturing to ensure optimal decision-making and operational excellence in the leadership of Integration Teams.

• Lead the effective translation of prioritization into resourcing needs across the ATs.

• Ensures membership of ATs reflect the need of the relevant product and are adequately resourced to support independent decision making.

• Leads the decision making on timing of establishing new ATs, considering when multiple registrational-intent tumor strategies are anticipated

• The Asset Team VP will manage individuals who lead multi-tumor asset teams (asset team leads). Any clinical development staff reporting to the ATL will be indirect reports.

Education:

• M.D or M.D./Ph.D.

• Ph.D. and/or Pharm.D candidates with more than 10 years of relevant industry experience

• Extensive knowledge of the oncology therapeutic area

Required Experience and Skills:

• Strong expertise in medical and translational sciences, clinical and predictive biomarker development, medical program design through all phases of clinical development

• Understands and demonstrates ownership of the commercialization of products through the pipeline

• Strong credibility in the scientific community, internally and externally, along with the ability to represent the company externally

• Multiple/varied experiences bringing a product through all cycles of development, including achieving product licensure with or without a companion or complementary predictive biomarker

• Proven ability in creating, driving a